King Investors Fail To Speed Suit Over $3.6B Pfizer Sale
Shareholders of King Pharmaceuticals Inc. have lost a bid to expedite their putative class action claiming the company's $3.6 billion sale to Pfizer Inc. is an attempt to cash in on...To view the full article, register now.
Already a subscriber? Click here to view full article